Clinical Trial Results: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout [Phase 4]

View source ↗

Summary

Phase 4 trial comparing pegylated uricase (pegloticase) given every 4 weeks with methotrexate vs every 2 weeks with methotrexate for uncontrolled refractory gou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Pegloticase (pegloticase)

Snippet

Sponsor: Amgen | Conditions: Gout | Phase 4 | Status: COMPLETED | Results posted: 2026-07-01